Page 50 - Read Online

Minami et al. Hepatoma Res 2020;6:46 I http://dx.doi.org/10.20517/2394-5079.2020.32 Page 11 of 11

resonance imaging for focal liver lesions: a meta-analysis. Ultrasound Med Biol 2011;37:854-61.
34. Chung YE, Kim KW. Contrast-enhanced ultrasonography: advance and current status in abdominal imaging. Ultrasonography 2015;34:3-
18.
35. Quaia E, De Paoli L, Angileri R, Cabibbo B, Cova MA. Indeterminate solid hepatic lesions identified on non-diagnostic contrast-
enhanced computed tomography: assessment of the additional diagnostic value of contrast-enhanced ultrasound in the noncirrhotic liver.
Eur J Radiol 2014;83:456-62.
36. Minami Y, Kudo M, Kawasaki T, Chung H, Ogawa C, et al. Treatment of hepatocellular carcinoma with percutaneous radiofrequency
ablation: usefulness of contrast harmonic sonography for lesions poorly defined with B-mode sonography. AJR Am J Roentgenol
2004;183:153-6.
37. Kim PN, Choi D, Rhim H, Rha SE, Hong HP, et al. Planning ultrasound for percutaneous radiofrequency ablation to treat small (≤ 3 Cm)
hepatocellular carcinomas detected on computed tomography or magnetic resonance imaging: a multicenter prospective study to assess
factors affecting ultrasound visibility. J Vasc Interv Radiol 2012;23:627-34.
38. Kim AY, Lee MW, Rhim H, Cha DI, Choi D, et al. Pretreatment evaluation with contrast-enhanced ultrasonography for percutaneous
radiofrequency ablation of hepatocellular carcinomas with poor conspicuity on conventional ultrasonography. Korean J Radiol
2013;14:754-63.
39. Rajesh S, Mukund A, Arora A, Jain D, Sarin SK. Contrast-enhanced US-guided radiofrequency ablation of hepatocellular carcinoma. J
Vasc Interv Radiol 2013;24:1235-40.
40. Eso Y, Takai A, Takeda H, Matsumoto T, Lee M, et al. Sonazoid-enhanced ultrasonography guidance improves the quality of pathological
diagnosis in the biopsy of focal hepatic lesions. Eur J Gastroenterol Hepatol 2016;28:1462-7.
41. Park HS, Kim YJ, Yu MH, Jung SI, Jeon HJ. Real-time contrast-enhanced sonographically guided biopsy or radiofrequency ablation of
focal liver lesions using perflurobutane microbubbles (sonazoid): value of Kupffer-phase imaging. J Ultrasound Med 2015;34:411-21.
42. Minami Y, Kudo M, Chung H, Kawasaki T, Yagyu Y, et al. Contrast harmonic sonography-guided radiofrequency ablation therapy versus
B-mode sonography in hepatocellular carcinoma: prospective randomized controlled trial. AJR Am J Roentgenol 2007;188:489-94.
43. Minami Y, Kudo M, Hatanaka K, Kitai S, Inoue T, et al. Radiofrequency ablation guided by contrast harmonic sonography using
perfluorocarbon microbubbles (Sonazoid) for hepatic malignancies: an initial experience. Liver Int 2010;30:759-64.
44. Masuzaki R, Shiina S, Tateishi R, Yoshida H, Goto E, et al. Utility of contrast-enhanced ultrasonography with Sonazoid in radiofrequency
ablation for hepatocellular carcinoma. J Gastroenterol Hepatol 2011;26:759-64.
45. Dohmen T, Kataoka E, Yamada I, Miura K, Ohshima S, et al. Efficacy of contrast-enhanced ultrasonography in radiofrequency ablation
for hepatocellular carcinoma. Intern Med 2012;51:1-7.
46. Minami T, Minami Y, Chishina H, Arizumi T, Takita M, et al. Combination guidance of contrast-enhanced US and fusion imaging
in radiofrequency ablation for hepatocellular carcinoma with poor conspicuity on contrast-enhanced US/fusion imaging. Oncology
2014;87:55-62.
47. Huang DY, Yusuf GT, Daneshi M, Ramnarine R, Deganello A, et al. Contrast-enhanced ultrasound (CEUS) in abdominal intervention.
Abdom Radiol (NY) 2018;43:960-76.
48. Kono Y, Lucidarme O, Choi SH, Rose SC, Hassanein TI, et al. Contrast-enhanced ultrasound as a predictor of treatment efficacy within 2
weeks after transarterial chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol 2007;18:57-65.
49. Xia Y, Kudo M, Minami Y, Hatanaka K, Ueshima K, et al. Response evaluation of transcatheter arterial chemoembolization in
hepatocellular carcinomas: the usefulness of sonazoid-enhanced harmonic sonography. Oncology 2008;75:99-105.
50. Zhou P, Kudo M, Minami Y, Chung H, Inoue T, et al. What is the best time to evaluate treatment response after radiofrequency ablation of
hepatocellular carcinoma using contrast-enhanced sonography? Oncology 2007;72:92-7.
51. Shiozawa K, Watanabe M, Kikuchi Y, Kudo T, Maruyama K, et al. Evaluation of sorafenib for hepatocellular carcinoma by contrast-
enhanced ultrasonography: a pilot study. World J Gastroenterol 2012 28;18:5753-8.
52. Sugimoto K, Moriyasu F, Saito K, Rognin N, Kamiyama N, et al. Hepatocellular carcinoma treated with sorafenib: early detection of
treatment response and major adverse events by contrast-enhanced US. Liver Int 2013;33:605-15.